PE/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CTL clone V4

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4⁺ T cell activation^1,4,11, thymocyte costimulation³, in vitro and in vivo depletion^2,5-8, blocking of egg-sperm cell adhesion^1,4, immunohistochemical staining of acetone-fixed frozen sections^9,10, immunoprecipitation^1,2, and spatial biology (IBEX)^12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes

BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Wang HH, et al. 2022. J Biomed Sci. 29:36. PubMed
2. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
3. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
4. Perruzza L, et al. 2019. Sci Rep. 9:9315. PubMed
5. Wang X, et al. 2019. Cell Res. 29:787. PubMed
6. Schönberger K, et al. 2022. Cell Stem Cell. 29:131. PubMed
7. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
8. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
9. Zhou J, et al. 2021. Int J Med Sci. 18:3516. PubMed
10. Garcia-Fabiani MB, et al. 2020. Methods Enzymol. 632:369. PubMed
11. Groza D, et al. 2018. Oncoimmunology. 7:e1424676. PubMed
12. Proietti M, et al. 2019. Nat Commun. 10:250. PubMed
13. Iwamoto H et al. 2018. Cell metabolism. 28(1):104-117 . PubMed
14. Hirata Y et al. 2018. Cell stem cell. 22(3):445-453 . PubMed
15. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
16. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
17. Saleh MM, et al. 2019. Cell Host Microbe. 25:756. PubMed
18. Fernandes RA, et al. 2020. eLife. 9:e58463.. PubMed
19. Diao L, et al. 2022. iScience. 25:105511. PubMed
20. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
21. Fitzgerald AA, et al. 2021. J Immunother Cancer. 9:. PubMed
22. Crespo ÂC, et al. 2020. Cell. 182(5):1125-1139. PubMed
23. Periasamy S, et al. 2017. Nat Commun. 8:15564. PubMed
24. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
25. Bowers E, et al. 2018. Nat Med. 24:95. PubMed
26. Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed
27. Schiller M, et al. 2021. Immunity. 54(5):1022-1036.e8. PubMed
28. Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed
29. Kaufmann U et al. 2019. Cell metabolism. 29(5):1104-1118 . PubMed
30. Matsuoka S, et al. 2019. Haematologica. 105:226. PubMed
31. Rolla S, et al. 2010. J Immunol. 184:6124. PubMed
32. Dai B, et al. 2022. Theranostics. 12:7603. PubMed
33. Ma YV, et al. 2021. MAbs. 13:2003281. PubMed
34. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
35. Haugh KA, et al. 2021. eLife. 0.416666666666667. PubMed
36. Wang C, et al. 2021. Cell Stem Cell. . PubMed
37. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
38. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
39. Ning X, et al. 2019. Mol Cell. 74:19. PubMed
40. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
41. Wang F, et al. 2021. Cell Mol Gastroenterol Hepatol. 13:257. PubMed
42. An J, et al. 2022. iScience. 25:103570. PubMed
43. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
44. Uchil PD et al. 2018. Cell host & microbe. 25(1):87-100 . PubMed
45. Wang H, et al. 2019. Nat Commun. 10:1898. PubMed
46. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
47. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
48. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
49. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
50. Ohmichi Y, et al. 2011. J Exp Med . 208:1015. PubMed
51. O'Brien S, Zhang M 2015. J Immunol. 195: 695-705. PubMed
52. Wang W, et al. 2020. Immunity. 51(6):1102-1118.e7.. PubMed
53. Pinho S, et al. 2022. Nat Cell Biol. 24:290. PubMed
54. Yang J, et al. 2022. Microbiome. 10:149. PubMed
55. Brandi P, et al. 2022. Cell Rep. 38:110184. PubMed
56. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
57. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
58. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
59. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
60. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
61. Akhter N, et al. 2016. J Biol Chem. 291: 23672 - 23680. PubMed
62. Sido J, et al. 2015. J Leukoc Biol. 98: 435-447. PubMed
63. Lee P, et al. 2014. J Immunol. 192:178. PubMed
64. Becher J, et al. 2018. Dev Cell. 47:592. PubMed
65. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
66. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
67. Luck H, et al. 2015. Cell Metab. 21 527 . PubMed
68. Faust HJ, et al. 2020. J Clin Invest. 130:5493. PubMed
69. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
70. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
71. Lim CX, et al. 2020. Cell Rep. 3793:30. PubMed
72. Zhou G, et al. 2019. FASEB J. 33:11396. PubMed
73. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
74. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
75. Dai R, et al. 2021. Front Immunol. 12:727046. PubMed
76. Li C, et al. 2021. Cell Metabolism. 33(8):1610-1623.e5. PubMed
77. Kondo M, et al. 2016. J Immunol. 196: 563 - 572. PubMed
78. XS R, et al. 2015. Diabetes. 64 90. PubMed
79. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
80. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
81. Cui Z, et al. 2021. Cell Death Dis. 12:775. PubMed
82. Kitajima Y, et al. 2022. Cells. 11:. PubMed
83. Busse DC, et al. 2020. J Virol. 94:00:00. PubMed
84. Koelwyn GJ, et al. 2020. Nat Med. 1452:26. PubMed
85. Lebel MÈ, et al. 2020. Nat Commun. 3.051388889. PubMed
86. Zhou J, et al. 2022. Int J Oncol. 61: . PubMed
87. Wang W, et al. 2021. J Am Heart Assoc. 10:e019142. PubMed
88. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
89. Godwin MS, et al. 2019. JCI Insight. 4:e126070. PubMed
90. Luck H, et al. 2019. Nat Commun. 10:3650. PubMed
91. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
92. Schönberger K, et al. 2022. STAR Protoc. 3:101408. PubMed
93. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
94. Kojima H, et al. 2021. Scand J Immunol. 93:e13020. PubMed
95. Wang W, et al. 2021. STAR Protocols. 2(3):100756. PubMed
96. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
97. Draijer C, et al. 2018. Sci Rep. 8:5105. PubMed
98. Isvoranu G, et al. 2019. Oncol Lett. 17:4197. PubMed
99. Li C, et al. 2018. Cell. 174:285. PubMed
100. Nakornpakdee Y, et al. 2018. Asian Pac J Allergy Immunol. 36:265. PubMed
101. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
102. Godwin MS, et al. 2021. Am J Physiol Lung Cell Mol Physiol. 320:L393. PubMed
103. Sanders K, et al. 2015. Cancer Immunol Res. 3: 891-901. PubMed
104. Chen M, et al. 2019. Cell Stem Cell. 25:501. PubMed
105. Kimura S, et al. 2020. Am J Transplant. 20:977. PubMed
106. Kelley WJ, et al. 2022. JCI Insight. 7: . PubMed
107. Kim S, et al. 2022. Cancers (Basel). 14:. PubMed
108. Prüss H, et al. 2017. Nat Neurosci. 10.1038/nn.4643. PubMed
109. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
110. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
111. Ambrosino E, et al. 2006. Cancer Res . 66:7734. PubMed
112. Nagamata S, et al. 2019. Sci Rep. 9:3911. PubMed
113. Schäfer AL, et al. 2021. Front Immunol. 12:696810. PubMed
114. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
115. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
116. Simula L, et al. 2022. Mol Oncol. 16:188. PubMed
117. RL M, et al. 2015. Proc Natl Acad Sci U S A. 112:6506-6514. PubMed
118. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
119. Lerbs T, et al. 2020. JCI Insight. 5:00. PubMed
120. Le TM et al. 2018. Journal of neurochemistry. 145(2):139-153 . PubMed
121. Sadtler K, et al. 2017. Tissue Eng Part A. 23:1044. PubMed
122. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
123. Kim YS, et al. 2018. Front Immunol. 9:1093. PubMed
124. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
125. Yu Z, et al. 2021. Biomed Res Int. 2021:9958745. PubMed
126. Amend A, et al. 2021. Int J Mol Sci. 22:. PubMed
127. Qi S, et al. 2020. Theranostics. 10:1814. PubMed
128. Groves HT, et al. 2020. MBio. 11:e03236-19. PubMed

RRID

AB_312706 (BioLegend Cat. No. 100421)
AB_312707 (BioLegend Cat. No. 100422)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis